NAD+ vs. NMN: How They Differ and What Trials Show

Last updated November 2, 2026 · Reviewed by the Gala Health team

Quick comparison

	NAD+	NMN	NR
What it is	The coenzyme itself	A precursor, one step before NAD+	A precursor that cells convert to NMN
Usual route	Injection through telehealth	Oral in most human trials	Oral in most human trials
Offered by Gala	Yes, as a subcutaneous injection	No	Only in small amounts within some GLP-1/GIP prescriptions
Human trial evidence	No eligible outcome trials of injected NAD+ for wellness found in a 2026 review	Raises blood NAD markers; effects on health outcomes mixed	Raises blood NAD markers; effects on health outcomes mixed

What each one is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. Cells use it in energy metabolism, and enzymes consume it as they work, so it is constantly being rebuilt.

NMN and NR (nicotinamide riboside) are precursors, molecules the body can use to make NAD+. They are sold as oral supplements and used in clinical trials. They are different compounds from NAD+, so results for one do not automatically carry over to another or to a different route.

How NMN becomes NAD+

A review in Nature Reviews Molecular Cell Biology describes the main route. When enzymes use up NAD+, they leave behind nicotinamide, which the salvage pathway recycles into NMN using an enzyme called NAMPT. NMN is then converted into NAD+ by a family of enzymes called NMNATs. NR can also be turned into NMN inside the cell, using the enzymes NRK1 and NRK2.

The same review adds a wrinkle for NMN that comes from outside the cell: it describes extracellular NMN being converted to NR by an enzyme called CD73 before it is imported, then converted back to NMN inside the cell by NRK1.

Injection vs. oral

Most human trials of NMN and NR use oral dosing. A 2026 systematic review of 113 studies (33 in humans) found that oral NR and NMN consistently raised NAD-related metabolites in blood or cells and were generally well tolerated over weeks to months. It found no eligible outcome trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness. One nonrandomized intravenous NMN study qualified and mainly contributed short-term safety and biomarker information.

That has a practical meaning. When you read that NMN or NR improved something in a trial, the people swallowed a capsule. When you read about NAD+ injections, you are looking at a different compound by a different route, and the human outcome data are thin. Gala's NAD+ is a subcutaneous injection you give at home after a provider reviews your intake.

What human trials of NMN found

Four randomized, placebo-controlled trials give a feel for the evidence. All were short, and each has its own limits:

Postmenopausal women with prediabetes who were overweight or obese (10 weeks, Washington University): muscle insulin sensitivity and insulin signaling increased after NMN and did not change after placebo. Two authors disclosed patent or licensing interests related to NMN.
Healthy older men (250 mg per day for 6 or 12 weeks, University of Tokyo): NMN was well tolerated and raised blood NAD+ levels. Improvements in gait speed and one grip test were only nominally significant and the authors said they should be validated in larger studies. There was no significant effect on body composition. Three authors are employees of Mitsubishi Corporation Life Sciences Limited.
80 healthy middle-aged adults (300, 600, or 900 mg per day for 60 days): blood NAD rose in all NMN groups, no safety issues were found, and six-minute walking distance was greater than with placebo. A measure of insulin resistance did not differ from placebo. Several authors are affiliated with companies in the NMN supply chain.
30 overweight or obese adults aged 45 and older (a high-dose NMN product for 28 days, Brigham and Women's Hospital): adverse events were similar between groups and blood NAD rose. Body weight, diastolic blood pressure, and cholesterol fell more than with placebo, but muscle strength, aerobic capacity, and insulin sensitivity did not differ. The study was small and short, and authors included affiliates of Metro International Biotech, which makes the NMN product.

Two broader reviews temper these results. The 2026 systematic review called clinical effectiveness for anti-aging or wellness inconclusive, with effects on functional and metabolic outcomes often null. A 2025 review in Nature Metabolism said human trials of NAD+ precursors have shown limited efficacy and that the age-related decline of NAD+ in humans has been consistently observed in only a limited number of studies.

Safety and side effects

In the trials above, oral NMN was reported as well tolerated over weeks to a few months, but those are short, small studies. Long-term safety has not been established. We did not find a published trial that measured side-effect rates for injected NAD+ or injected NMN in healthy adults, so we cannot give you numbers for either. Our guide to NAD+ injection side effects covers what is known.

Gala's intake screens out a hematocrit of 52% or higher and a known allergy to NAD. Tell your provider about every medicine and supplement you take, including any NMN or NR product, so they can see the full picture.

Regulatory status

The two products sit in different regulatory categories, and NMN's has changed.

NMN: whether NMN can be sold as a dietary supplement is a regulatory question for the FDA. This status says nothing about whether NMN works. A company that wants to market NMN as a new dietary ingredient files a notification with the FDA, and the FDA's own list of submitted notifications shows an NMN notification received on November 17, 2025, with an FDA response dated January 28, 2026. Check the FDA's current documents for the agency's position before relying on any summary.

NAD+ injections offered by telehealth companies are typically compounded. Compounded medications are not FDA-approved. The FDA states that it does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Nicotinamide adenine dinucleotide (NAD) appeared on the FDA's Category 1 list of bulk substances under evaluation for compounding in the version updated May 14, 2026. Category 1 is not an approval and not a finding that NAD+ works.

How to think about the choice

The question is rarely NAD+ or NMN in the abstract. It is what you want, how much evidence exists for it, and what you are comfortable with. Questions worth asking a provider: What is the evidence for my goal? How would we tell whether it is working? Which pharmacy makes this product? Does anything I take already change the picture? Be wary of any seller who promises results or cannot say where the product is made.

How Gala's longevity program works

You complete an online health questionnaire, and a licensed provider reviews it asynchronously, with no video call required. If NAD+ is appropriate, your provider confirms the dosing before anything ships. See NAD+ at Gala, read what NAD+ is, or browse the full longevity program. To see whether you qualify, start your online longevity intake.

This article is general education, not medical advice. Talk to a clinician about your own health history.

Frequently asked questions

Is NMN the same as NAD+?

No. NAD+ is the coenzyme itself. NMN is a precursor that cells convert into NAD+ through a series of enzymes. They are different compounds, and results for one do not automatically apply to the other.

Is NMN better than NAD+ injections?

We cannot say that. Most human trials tested oral NMN, while a 2026 systematic review found no eligible outcome trials of injected NAD+ for wellness. No head-to-head trial comparing the two came up in our review.

Does NMN raise NAD+ levels?

In the randomized trials we reviewed, oral NMN raised blood NAD or related metabolites. Whether that translates into health benefits is less clear: the 2026 systematic review found effects on functional and metabolic outcomes were mixed and often null.

Is NMN legal to sell as a supplement?

Whether NMN can be sold as a dietary supplement is decided by the FDA. Its public list of new dietary ingredient notifications includes an NMN notification with an FDA response dated January 28, 2026. Check the FDA's own documents for the current position.

Is NAD+ FDA-approved?

No. NAD+ injections from telehealth providers are typically compounded, and compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed.

Ready to talk to a provider?

Your answers go to a licensed provider, who decides whether treatment is right for you. Learn more about Longevity.

Start your longevity intake

Sources

This article is for general information and is not medical advice. Talk to a licensed provider about your own health.